JP2021534815A5 - - Google Patents

Info

Publication number
JP2021534815A5
JP2021534815A5 JP2021531201A JP2021531201A JP2021534815A5 JP 2021534815 A5 JP2021534815 A5 JP 2021534815A5 JP 2021531201 A JP2021531201 A JP 2021531201A JP 2021531201 A JP2021531201 A JP 2021531201A JP 2021534815 A5 JP2021534815 A5 JP 2021534815A5
Authority
JP
Japan
Prior art keywords
domain
human
car according
cells
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021534815A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/000907 external-priority patent/WO2020030979A2/en
Publication of JP2021534815A publication Critical patent/JP2021534815A/ja
Publication of JP2021534815A5 publication Critical patent/JP2021534815A5/ja
Priority to JP2024099001A priority Critical patent/JP2024123133A/ja
Pending legal-status Critical Current

Links

JP2021531201A 2018-08-10 2019-08-09 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物 Pending JP2021534815A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024099001A JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862717234P 2018-08-10 2018-08-10
US62/717,234 2018-08-10
PCT/IB2019/000907 WO2020030979A2 (en) 2018-08-10 2019-08-09 New car constructs comprising tnfr2 domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024099001A Division JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Publications (2)

Publication Number Publication Date
JP2021534815A JP2021534815A (ja) 2021-12-16
JP2021534815A5 true JP2021534815A5 (https=) 2022-08-17

Family

ID=68470557

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021531201A Pending JP2021534815A (ja) 2018-08-10 2019-08-09 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物
JP2024099001A Pending JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024099001A Pending JP2024123133A (ja) 2018-08-10 2024-06-19 Ｔｎｆｒ２ドメインを含む新規ｃａｒ構築物

Country Status (12)

Country Link
US (1) US20210292389A1 (https=)
EP (1) EP3833446A2 (https=)
JP (2) JP2021534815A (https=)
KR (1) KR20210046006A (https=)
CN (1) CN112888481A (https=)
AU (1) AU2019318135A1 (https=)
BR (1) BR112021002579A2 (https=)
CA (1) CA3109253A1 (https=)
IL (1) IL280697A (https=)
MX (1) MX2021001592A (https=)
SG (1) SG11202101415UA (https=)
WO (1) WO2020030979A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
EP3808766A1 (en) * 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
WO2021183795A1 (en) * 2020-03-11 2021-09-16 Poseida Therapeutics, Inc. Chimeric stimulatory receptors and methods of use in t cell activation and differentiation
CN113528449A (zh) * 2020-04-20 2021-10-22 浙江瑞加美生物科技有限公司 一种制备通用型人源化car19-dnt细胞的技术及其应用
JP7825834B2 (ja) * 2021-01-20 2026-03-09 ソウル ナショナル ユニバーシティ アールアンドディビー ファウンデーション 抗ｃ４ｄキメラ抗原受容体調節性ｔ細胞およびその使用
JP2024526201A (ja) * 2021-06-25 2024-07-17 サンガモ セラピューティクス，インコーポレイテッド Ｉｌ－２３ｒに特異的な抗原結合体及びその使用
EP4376859A4 (en) * 2021-07-29 2025-07-30 Sonoma Biotherapeutics Inc SYNOVIAL EXTRACELLULAR MATRIX-SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR TARGETING REGULATORY T CELLS TO TREAT AUTOIMMUNE DISEASES
US20240382525A1 (en) * 2021-10-26 2024-11-21 Gavish-Galilee Bio Applications Ltd. Cd4+ and/or cd8+ cell populations comprising icars for use in treatment therapies
CN114262689A (zh) * 2021-12-17 2022-04-01 上海纳米技术及应用国家工程研究中心有限公司 一种快速检测cd19/cd20-car-t细胞活性的方法
EP4479143A1 (en) * 2022-02-18 2024-12-25 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
WO2025006795A1 (en) * 2023-06-30 2025-01-02 Board Of Regents, The University Of Texas System Tsyn-seq: a t cell synapse-based tumor antigen identification platform
WO2025170881A1 (en) * 2024-02-06 2025-08-14 The Board Of Trustees Of The University Of Illinois Methods and kits for reducing the risk of allograft rejection
WO2025250847A1 (en) * 2024-05-29 2025-12-04 The Texas A&M University System Compositions containing hsp60-specific regulatory t cells and methods of treatment using the same

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
ES2298745T3 (es) 2003-04-24 2008-05-16 Fondazione Centro San Raffaele Del Monte Tabor Promotores bidireccionales de sintesis y utilizacion de los mismos.
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
EP2126054B1 (en) 2007-01-31 2016-07-06 Yeda Research And Development Company Limited Redirected, genetically-engineered t regulatory cells and their use in suppression of autoimmune and inflammatory disease
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
AU2011281062B2 (en) 2010-07-21 2015-01-22 Board Of Regents, The University Of Texas System Methods and compositions for modification of a HLA locus
CA2832540C (en) 2011-04-08 2020-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CN113355357B (zh) 2012-12-12 2024-12-03 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
EP2840140B2 (en) 2012-12-12 2023-02-22 The Broad Institute, Inc. Crispr-Cas based method for mutation of prokaryotic cells
ES2918501T3 (es) * 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
EP3087101B1 (en) * 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
ES2857226T3 (es) * 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
AU2015301460B2 (en) * 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
WO2016184570A1 (en) 2015-05-18 2016-11-24 Numab Ag Novel treatment methods based on multifunctional molecules
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CA3019650C (en) * 2016-04-01 2023-07-25 Kite Pharma, Inc. Chimeric receptors and methods of use thereof
JP7100028B2 (ja) * 2016-10-20 2022-07-12 セルジーン コーポレイション セレブロン系のヘテロ二量体化可能なキメラ抗原受容体
WO2018106993A1 (en) * 2016-12-09 2018-06-14 H. Lee Moffitt Cancer Center And Research Institute Inc. Tlr9-binding chimeric antigen receptors
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
US11827705B2 (en) 2017-03-28 2023-11-28 The Trustees Of The University Of Pennsylvania Methods to protect transplanted tissue from rejection
SG11202002520UA (en) 2017-09-19 2020-04-29 Univ British Columbia Anti-hla-a2 antibodies and methods of using the same

Similar Documents

Publication Publication Date Title
JP2021534815A5 (https=)
JP6574848B2 (ja) Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ）
CN106536563B (zh) 嵌合抗原受体
JP6936497B2 (ja) 多価Ｆｖ抗体
JP2023527049A5 (https=)
US20210177951A1 (en) Engineered cells & methods
JP2018521663A5 (https=)
JP2016520074A5 (https=)
JP2021511041A5 (https=)
WO2020017479A1 (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
CN112739721A (zh) 一种单域抗体及包含抗体结构的嵌合抗原受体
JP2007530435A5 (https=)
JP2022505445A5 (https=)
JP2016538855A5 (https=)
JP2017500869A5 (https=)
JP2021525534A5 (https=)
JP2023518538A5 (https=)
JP2021506275A5 (https=)
WO2023193662A1 (zh) 靶向bcma的嵌合抗原受体及其应用
JP2024507540A5 (https=)
CN114249832B (zh) 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
JP2018502068A5 (https=)
JP2020535811A5 (https=)
CN111417720A (zh) 用于选择性扩增表达具有鼠恒定区的tcr的细胞的方法
JP2023541456A5 (https=)